Is zoledronic acid an immunosuppressant?

Is zoledronic acid an immunosuppressant?

Thanks to its ability to decrease Ras/ERK1/2 activity, which is responsible for both Pgp-mediated chemoresistance and IDO-mediated immunosuppression, zoledronic acid is an effective chemo-immunosensitizing agent in HMM cells.

Is zoledronic acid a chemo drug?

Zoledronic acid (Zometa) is not cancer chemotherapy, and it will not slow or stop the spread of cancer. However, it can be used to treat bone disease in patients who have cancer. Zoledronic acid is in a class of medications called bisphosphonates.

Is zoledronic acid FDA approved?

The US Food and Drug Administration (FDA) has approved zoledronic acid (Zometa) for the treatment of bone complications in patients with multiple myeloma and patients with solid tumors, in conjunction with standard antineoplastic therapy.

What are the side effects of zoledronic acid?

More common

• Abdominal or stomach pain.
• back pain.
• bad, unusual, or unpleasant (after) taste.
• bladder pain.
• blistering, crusting, irritation, itching, or reddening of the skin.
• bone pain.
• burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings.
• change in taste.

Do bisphosphonates affect immune system?

This work suggests that bisphosphonates have the potential to depress the innate immune system for a prolonged time, possibly contributing to the pathogenesis of BRONJ.

How long does zoledronic acid stay in the body?

The excretion of zoledronic acid by the kidney does not depend on the dose or the infusion time (Chen et al 2002). The drug can be detected in urine in trace amounts up to 28 days after the infusion, although adequate amounts are present in urine only in the first 24 hours (Chen et al 2002).

Is zoledronic acid infusion safe?

Zoledronic acid had an acceptable safety profile; no adverse events were considered to be drug related. Treatment with ZA improved bone health by enhancing bone mineral density and reducing bone turnover, even in high-risk patients.

How long does zoledronic acid stay in your system?

When was zoledronic acid approved by FDA?

Approval Date: 2/22/2002.

When was reclast approved by FDA?

Approval Date: 8/17/2007.

Does zoledronic acid affect the heart?

Patients treated with zoledronic acid had a higher risk for heart failure, among other cardiovascular conditions, according to a study presented at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting held September 8-11 in Denver, Colorado.

What is zoledronate infusion?

Aclasta. Zoledronic acid is an osteoporosis medication prescribed to help strengthen your bones and reduce your risk of breaking a bone. It is available as an annual intravenous infusion (drip). Zoledronic acid is a ‘bisphosphonate’ – a group of medications that work by slowing down the cells that break down bone.